Thyroid Eye Disease (TED) Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies

April 11 22:02 2023
Thyroid Eye Disease (TED) Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight, the Thyroid Eye Disease therapeutics market is anticipated to evolve immensely in the coming years owing to the increasing prevalent population of Thyroid eye disease patients, the rise in the geriatric population, government support for clinical development, and the launch of novel therapies.

Several major pharma and biotech companies are persistently working towards the development of novel treatment therapies that can address Thyroid eye disease. There are several promising drugs in the pipeline which include VRDN—001 (Viridian Therapeutics), Secukinumab (Novartis), and IMVT-1401 (Immunovant Sciences GmbH) among others. VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R).

Thyroid Eye Disease (TED) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Thyroid Eye Disease Market. 

The Thyroid Eye Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Thyroid Eye Disease (TED) Pipeline Analysis

Thyroid Eye Disease (TED) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Thyroid Eye Disease and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Thyroid Eye Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Learn How the Ongoing Clinical & Commercial Activities will Affect the Thyroid Eye Disease Therapeutic Segment @

The Leading Companies in the Thyroid Eye Disease (TED) Therapeutics Market Include:

  • Novartis

  • Viridian Therapeutics

  • Immunovant Sciences GmbH 

  • Horizon Therapeutics

And Many Others

Thyroid Eye Disease (TED) Marketed and Emerging Drugs Covered in the Report Include:

  • TEPEZZA (teprotumumab): 

  • Secukinumab: Novartis

  • VRDN-001: Viridian Therapeutics

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Thyroid Eye Disease Current Treatment Patterns

4. Thyroid Eye Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Thyroid Eye Disease Late Stage Products (Phase-III)

7. Thyroid Eye Disease Mid-Stage Products (Phase-II)

8. Thyroid Eye Disease Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Thyroid Eye Disease Discontinued Products

13. Thyroid Eye Disease Product Profiles

14. Key Companies in the Thyroid Eye Disease Market

15. Key Products in the Thyroid Eye Disease Therapeutics Segment

16. Dormant and Discontinued Products

17. Thyroid Eye Disease Unmet Needs

18. Thyroid Eye Disease Future Perspectives

19. Thyroid Eye Disease Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


Take control of your pharmaceutical portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your pharmaceutical portfolio today @ Pharmaceutical Portfolio Management Services 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States